Atsushi Kuno (Tsukuba / JP), Yuki Yamaguchi (Suita / JP), Kentaro Ishii (Suita / JP), Sachiko Koizumi (Matsudo / JP; Yokohama / JP), Hiroaki Sakaue (Tsukuba / JP), Takahiro Maruno (Suita / JP), Mitsuko Fukuhara (Suita / JP), Risa Shibuya (Suita / JP), Yasuo Tsunaka (Suita / JP), Aoba Matsushita (Suita / JP), Karin Bandoh (Suita / JP), Tetsuo Torisu (Suita / JP), Chie Murata-Kishimoto (Yokohama / JP), Azusa Tomioka (Tsukuba / JP), Saho Mizukado (Tsukuba / JP), Sayaka Fuseya (Tsukuba / JP), Hiroyuki Kaji (Nagoya / JP), Yuji Kashiwakura (Shimotsuke / JP), Tsukasa Ohmori (Shimotsuke / JP), Susumu Uchiyama (Suita / JP)
Glycan analysis of viral vectors is important from the viewpoint of quality evaluation of pharmaceuticals. Due to recent advances in analytical technology, glycosylation of several adeno-associated viruses (AAVs) has been reported. However, the obtained glycosylation pattern and structure are varied and still controversial, suggesting that data acquisition and interpretation using a standardized analytical method are required [1]. In this study, we developed an in-depth analytical method for glycosylation of several serotypes of AAVs using multimodal glycan omics technologies [2]. In brief, 25 recombinant AAVs (rAAVs) among 6 different serotypes were initially subjected to an ultrasensitive lectin microarray we recently improved [3]. Significant signals on O-glycan binding lectins were observed only in rAAV6. The subsequential liquid chromatography-tandem mass spectrometry (LC-MS/MS), combined with the pre-enrichment step using an O-glycan binding lectin and with the post-MS step for glycopeptide identification using a software GRable [4], enabled us to find the mucin-type glycans on viral protein 2 of rAAV6. Interestingly, the glycosylated rAAV6 had a much lower VP1 to VP2/VP3 ratio than non-glycosylated rAAV6. The difference in component proportion leads to the reduced transduction efficiency of rAAV6 [5].
This study was supported by a grant-in-aid from the 'Research and development of core technologies for gene and cell therapy' supported by the Japan Agency for Medical Research and Development (AMED) [grant number JP18ae0201001 and JP18ae0201002].
References
[1] Rumachik N.G., et al., Mol. Ther. Methods Clin. Dev., 18, 98-118 (2020).
[2] Hiono T., et al., J. Proteome Res., 23, 1408-19 (2024).
[3] Boottanun P., et al., Anal. Bioanal. Chem., 415, 6975-84 (2023).
[4] Nagai-Okatani C., et al., bioRxiv (2024). doi:10.1101/2023.10.30.564073.
[5] Yamaguchi Y., et al., Mol. Ther. Methods Clin. Dev., 32, 101256 (2024).
We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.